文献速递心律失常血脂与心血管预防

房颤患者传统与直接抗凝药治疗下的骨质疏松性骨折风险

Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

基于丹麦全国登记数据,纳入37,350例无既往骨质疏松用药且接受180天口服抗凝治疗的房颤患者,比较维生素K拮抗剂(VKA)与直接口服抗凝药(DOAC)的骨质疏松性骨折风险。DOAC组任何骨折2年标准化绝对风险为3.1%(95%CI 2.9%-3.3%),VKA组为3.8%(95%CI 3.4%-4.2%);DOAC与任何骨折、主要骨质疏松性骨折及启动骨质疏松药物治疗的相对风险显著更低。

要点

  • 房颤患者口服抗凝治疗中骨质疏松性骨折绝对风险较低。
  • DOAC较VKA与任何骨折风险显著降低相关(HR 0.85,95%CI 0.74-0.97)。
  • DOAC较VKA与启动骨质疏松药物治疗风险显著降低相关(HR 0.82,95%CI 0.71-0.95)。

核心结论

  • 在房颤口服抗凝患者中骨质疏松性骨折绝对风险低,但DOAC较VKA与骨质疏松性骨折风险显著降低相关。

研究设计与样本

  • 基于丹麦国家登记数据的全国性队列研究,纳入37,350例无既往骨质疏松用药且接受180天口服抗凝治疗的房颤患者。

主要发现

  • DOAC组任何骨折2年标准化绝对风险为3.1%(95%CI 2.9%-3.3%),VKA组为3.8%(95%CI 3.4%-4.2%)。
  • DOAC与任何骨折风险显著降低相关(HR 0.85,95%CI 0.74-0.97)。
  • DOAC与主要骨质疏松性骨折风险显著降低相关(HR 0.85,95%CI 0.72-0.99)。
  • DOAC与启动骨质疏松药物治疗风险显著降低相关(HR 0.82,95%CI 0.71-0.95)。
  • DOAC与任何骨折或启动骨质疏松药物治疗复合终点风险显著降低相关(HR 0.84,95%CI 0.76-0.93)。

临床怎么用

  • 房颤患者选择口服抗凝药时,可将DOAC相较于VKA的较低骨质疏松性骨折风险作为综合考虑因素之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures. OBJECTIVES: The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA or direct oral anticoagulants (DOACs). METHODS: Patients were identified using the Danish national registries. Patients were included only if they had no prior use of osteoporosis medication and they had undergone 180 days of OAC treatment. Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint. RESULTS: Overall, 37,350 patients were included. The standardized absolute 2-year risk of any fracture was low among DOAC-treated patients (3.1%; 95% CI: 2.9% to 3.3%) and among VKA-treated patients (3.8%; 95% CI: 3.4% to 4.2%). DOAC was associated with a significantly lower relative risk of any fracture (hazard ratio [HR]: 0.85; 95% CI: 0.74 to 0.97), major osteoporotic fractures (HR: 0.85; 95% CI: 0.72 to 0.99), and initiating osteoporotic medication (HR: 0.82; 95% CI: 0.71 to 0.95). A combined endpoint showed that patients treated with DOAC had a significantly lower relative risk of experiencing any fracture or initiating osteoporosis medication (HR: 0.84; 95% CI: 0.76 to 0.93). CONCLUSIONS: In a nationwide population, the absolute risk of osteoporotic fractures was low among patients with atrial fibrillation on OAC, but DOAC was associated with a significantly lower risk of osteoporotic fractures compared with VKA.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Binding C, Bjerring Olesen J, Abrahamsen B, et al. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. J Am Coll Cardiol. 2019. PMID: 31648707. doi:10.1016/j.jacc.2019.08.1025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。